Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-jRCT2080222108
JPRN-jRCT2080222108
Unknown
Phase 3

Open-label, multicenter study to assess the efficacy, safety, tolerability, and pharmacokinetics of bosentan in Japanese children with pulmonary arterial hypertension

Actelion Pharmaceuticals Japan Ltd.0 sites5 target enrollmentJune 11, 2013
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsPulmonary arterial hypertension (PAH)

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Pulmonary arterial hypertension (PAH)
Sponsor
Actelion Pharmaceuticals Japan Ltd.
Enrollment
5
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 11, 2013
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Actelion Pharmaceuticals Japan Ltd.

Eligibility Criteria

Inclusion Criteria

  • •Idiopathic PAH, Heritable PAH, PAH associated with CHD

Exclusion Criteria

  • •Co\-exisiting hepatic impairment etc.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Gadobutrol/Gadavist-enhanced cardiac magnetic resonance imaging (CMRI) to detect Coronary Artery Disease (CAD)Subjects with known or suspected Coronary Artery Disease (CAD)Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
EUCTR2012-002563-10-GBBayer AG426
Active, not recruiting
Phase 1
Gadobutrol/Gadavist-enhanced cardiac magnetic resonance imaging (CMRI) to detect Coronary Artery Disease (CAD)
EUCTR2012-002563-10-DEBayer HealthCare AG450
Active, not recruiting
Phase 1
Gadobutrol/Gadavist-enhanced cardiac magnetic resonance imaging (CMRI) to detect Coronary Artery Disease (CAD)Subjects with known or suspected Coronary Artery Disease (CAD)Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
EUCTR2012-002563-10-FRBayer HealthCare AG450
Active, not recruiting
Not Applicable
A multicenter, open-label study on the efficacy, cycle control and safety of a contraceptivevaginal ring delivering a daily dose of 150 µg of Nestorone(R) and 15 µg of ethinyl estradiol (150/15 NES/EE CVR)As the trial is intended to investigate a new contraceptive medicinal product, the study subjects included are not characterized by a specific medical condition.MedDRA version: 8.1Level: PTClassification code 10010808Term: Contraception
EUCTR2005-004978-25-HUInternational Committee for Contraception Research of the Population Council2,200
Active, not recruiting
Not Applicable
A multicenter, open-label study on the efficacy, cycle control and safety of a contraceptivevaginal ring delivering a daily dose of 150 µg of Nestorone(R) and 15 µg of ethinyl estradiol (150/15 NES/EE CVR)As the trial is intended to investigate a new contraceptive medicinal product, the study subjects included are not characterized by a specific medical condition.MedDRA version: 8.1Level: PTClassification code 10010808Term: Contraception
EUCTR2005-004978-25-SEInternational Committee for Contraception Research of the Population Council2,200